|
1
|
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
|
Neuropsychopharmacology
|
2007
|
1.08
|
|
2
|
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
|
Pharmacol Biochem Behav
|
2008
|
0.89
|
|
3
|
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms.
|
CNS Drug Rev
|
2003
|
0.89
|
|
4
|
Intermittent stick-slip dynamics during the peeling of an adhesive tape from a roller.
|
Phys Rev E Stat Nonlin Soft Matter Phys
|
2013
|
0.88
|
|
5
|
Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress.
|
Behav Brain Res
|
2009
|
0.87
|
|
6
|
Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models.
|
Pharmacol Biochem Behav
|
2007
|
0.82
|
|
7
|
Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
|
Neuropsychopharmacology
|
2004
|
0.81
|
|
8
|
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
|
Psychopharmacology (Berl)
|
2010
|
0.80
|
|
9
|
Antidepressant-like effects of the corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, in a DRL-72 s schedule in the rat.
|
Neuropsychopharmacology
|
2006
|
0.80
|
|
10
|
The corticotropin-releasing factor 1 receptor antagonist, SSR125543, and the vasopressin 1b receptor antagonist, SSR149415, prevent stress-induced cognitive impairment in mice.
|
Pharmacol Biochem Behav
|
2011
|
0.78
|
|
11
|
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition.
|
Pharmacol Biochem Behav
|
2010
|
0.75
|